BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is a clinical-stage, publicly-traded biotechnology company focused on the development of best-in-class autologous cellular therapeutics for the treatment of highly debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) released its quarterly earnings data on Thursday, October, 15th. Shares of BrainStorm Cell Therapeutics (NASDAQ:BCLI) fell off a cliff Tuesday, and were down by 67% as of 12:20 p.m. EST after being down by as much as … MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. BrainStorm launches NurOwn Expanded Access Program Dec. 14, 2020 8:46 AM ET Brainstorm Cell Therapeutics Inc. (BCLI) By: Mamta Mayani , SA News Editor 4 Comments Brainstorm Cell Therapeutics was expecting to see response rates of 35% for its drug compared to 15% for the placebo. On average, they anticipate Brainstorm Cell Therapeutics' share price to reach $20.00 in the next year. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares. Brainstorm Cell Therapeutics employs 44 workers across the globe. Brainstorm Cell Therapeutics was expecting to see response rates of 35% for its drug compared to 15% for the placebo. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. View Brainstorm Cell Therapeutics' earnings history. Brainstorm Cell Therapeutics -7% despite earnings beat seekingalpha.com - October 15 at 5:33 PM: Brainstorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q3 2020 Results - Earnings Call Transcript seekingalpha.com - October 15 at 5:33 PM: BrainStorm Cell Therapeutics EPS beats by $0.12 seekingalpha.com - October 15 at 7:31 AM The problem comes from the placebo response rate, which was 27.7%. About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics … You may vote once every thirty days. (Add your “outperform” vote. Brainstorm Cell Therapeutics Inc Dec 18, 2020, 07:00 ET. The biotechnology company earns $-23,250,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Down 28.5% In 24 Hours, Where Does Ethereum (ETH) Go From Here? NEW YORK, Dec. 18, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics … In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock. Since then, BCLI shares have decreased by 20.7% and is now trading at $5.30. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went down by -4.33% from its latest closing price compared to the recent 1-year high of $17.95. NEW YORK, Dec. 28, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics … We are in active discussions with the FDA who have expressed their eagerness to review the data and have committed to prioritize review of this data. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. Only 21.58% of the stock of Brainstorm Cell Therapeutics is held by institutions. Brainstorm Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings. A great summary of the facts can be found in this Seeking Alpha article on the subject. Article printed from InvestorPlace Media, https://investorplace.com/2020/11/brainstorm-cell-therapeutics-als-study-news/. Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. View all of BCLI's competitors. quotes delayed at least 15 minutes, all others at least 20 minutes. Instead, its response … 1125 N. Charles St, Baltimore, MD 21201. All rights reserved. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. CubeSmart (NYSE: CUBE) Stock is a Smart Pullback Play, Capstone Turbine (NASDAQ: CPST) Stock a Clean Energy Turbine Play, 3D Printing Stocks Offering Another Dimension of Gains, MicroStrategy (NASDAQ:MSTR) Slips on Troubles in Bitcoin. View insider buying and selling activity for Brainstorm Cell Therapeutics or or view top insider-buying stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. About BCLI. To see all exchange delays and terms of use please see disclaimer. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 The consensus among Wall Street analysts is that investors should "hold" Brainstorm Cell Therapeutics stock. Wall Street analysts have given Brainstorm Cell Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. © American Consumer News, LLC dba MarketBeat® 2010-2021. Company insiders that own Brainstorm Cell Therapeutics stock include David Setboun, International Holdings Ltd Acc, Irit Arbel, Preetam Shah, Ralph Dr Kern and Sankesh Abbhi. There are currently 1 hold rating for the stock. Get short term trading ideas from the MarketBeat Idea Engine. Brainstorm Cell Therapeutics has a market capitalization of $167.31 million. The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com. Looking for new stock ideas? Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. … All rights reserved. BrainStorm Issues 2020 Letter to Shareholders Mon, December 28, 2020, 2:00 PM GMT+2 NEW YORK, Dec. 28, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a … 2021 InvestorPlace Media, LLC. One share of BCLI stock can currently be purchased for approximately $5.30. After a Post-Earnings Drop, is it Time to Ride PetMed Express? News provided by. That’s an unusually high placebo rate compared to other ALS studies and Brainstorm Cell Therapeutics’ own Phase 2 results. Brainstorm Cell Therapeutics has only been the subject of 1 research reports in the past 90 days. We identified a superior treatment response in a pre-specified subgroup of patients with less advanced disease. NEW YORK, Dec. 28, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the … Identify stocks that meet your criteria using seven unique stock screeners. BCLI stock was down 66.4% as of noon Tuesday. Want to see which stocks are moving? Brainstorm Cell Therapeutics' stock is owned by a variety of institutional and retail investors. Jan. 22, 2021, CCIV Stock: Lucid Motors SPAC Merger Rumors Send Churchill Capital Climbing Again, How the Internet Sent GameStop Stock Up 1,000% — And Where It’s Going Next, While It’s Holding Steady Now, Get Ready to Bail on Palantir Stock, Don’t Buy CCIV Stock Now. Learn more. View which stocks are hot on social media with MarketBeat's trending stocks report. View our full suite of financial calendars and market data tables, all for free. Get the latest Brainstorm Cell Therapeutics In (BCLI) stock news and headlines to help you in your trading and investing decisions. 1125 N. Charles St, Baltimore, MD 21201. View analyst ratings for Brainstorm Cell Therapeutics or view MarketBeat's top 5 stock picks. Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 Copyright © 2021 InvestorPlace Media, LLC. Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Brainstorm Cell Therapeutics News: 8 Things for BCLI Stock Investors to Know About the ALS Study, Louis Navellier and the InvestorPlace Research Staff, A Play on the Biggest Scientific Breakthrough of the Century, What Did the Stock Market Do? Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Brainstorm Cell Therapeutics has received a consensus rating of Hold. Learn everything you need to know about successful options trading with this three-part video course. Learn about financial terms, types of investments, trading strategies and more. The company revealed topline results from its Phase 3 trial of NurOwn to treat ALS. (Add your “underperform” vote.). Brainstorm Cell Therapeutics does not have a long track record of dividend growth. This suggests a possible upside of 277.4% from the stock's current price. BrainStorm Cell Therapeutics Inc. is dedicated to developing innovative cellular therapies for highly debilitating neurodegenerative diseases. The therapy is currently … Brainstorm Cell Therapeutics does not currently pay a dividend. The company’s stock price has collected -0.09% of loss in the last five trading sessions. Instead, its response rate came in at 34.7%, which is close to the 35% it was aiming for. Brainstorm Cell Therapeutics' management team includes the following people: Co-Founder & Independent Vice Chair of the Board, Start Your Risk-Free Trial Subscription Here, 3 Clean Energy Stocks that Could Get Boosted by Biden, Biden ordering stopgap help as talks start on big aid plan, Why These 3 ETFs Should be in Your 2021 Portfolio, Chipmaker Intel Corp. blames internal error on data leak, Biden's pause on oil cause for big concern in New Mexico, Biden halts border wall building after Trump's final surge, Buy Kinder Morgan, Inc While It Still Yields 6.75%. According to analysts' consensus price target of $20.00, Brainstorm Cell Therapeutics has a forecasted upside of 277.4% from its current price of $5.30. NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for … MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO), Isoray (ISR), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP). BrainStorm Cell Therapeutics is sharing the details of the design of its Phase 3 clinical trial evaluating NurOwn as a treatment for people with rapidly progressing amyotrophic lateral sclerosis (ALS), showing that the trial is adequately powered to detect meaningful improvements in patients. Brainstorm Cell Therapeutics has received 59.14% “outperform” votes from our community. Brainstorm Cell Therapeutics Inc 28 Dec, 2020, 14:00 IST. NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. See what's happening in the market right now with MarketBeat's real-time news feed. But Pounce on the Lucid Motors Merger, CCIV Stock: Comparing Lucid Motors to Tesla as ‘Merger Monday’ Hopes Soar. 1 brokers have issued 1 year target prices for Brainstorm Cell Therapeutics' stock. Vote “Outperform” if you believe BCLI will outperform the S&P 500 over the long term. BCLI stock was purchased by a variety of institutional investors in the last quarter, including Epiq Partners LLC. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include David Setboun, Preetam Shah, Ralph Dr Kern, and Sankesh Abbhi. All rights reserved. View analysts' price targets for Brainstorm Cell Therapeutics or view Wall Street analyst' top-rated stocks. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing has been completed in the ongoing... Dec 14, 2020 BrainStorm Announces NurOwn® Expanded Access Program View our earnings forecast for Brainstorm Cell Therapeutics. BrainStorm is focused on developing clinical-stage autologous cellular therapy as a potentially transformative approach to treating neurodegenerative diseases. The company has a partnership with Catalent for the manufacture of NurOwn, an autologous cellular therapy. Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, said this about the news. 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. BCLI | Complete Brainstorm Cell Therapeutics Inc. stock news by MarketWatch. Copyright © Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the following letter from its Chief Executive Officer,... Dec 18, 2020 BrainStorm Announces Completion of All Dosing in NurOwn® Phase 2 MS Study Fundamental company data provided by Morningstar and Zacks Investment Research. Share this article. The P/E ratio of Brainstorm Cell Therapeutics is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Learn more. Brainstorm Cell Therapeutics (NASDAQ:BCLI) news for Tuesday has BCLI stock taking a beating following results from its Amyotrophic lateral sclerosis (ALS) study. This has it missing its primary endpoint, which was determining NurOwn’s effectiveness compared to a placebo. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today … Export data to Excel for your own analysis. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Press Release reported on 11/23/20 that BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND You can opt out at any time. ), Brainstorm Cell Therapeutics has received 199 “underperform” votes. Brainstorm Cell Therapeutics has received 288 “outperform” votes. Get daily stock ideas top-performing Wall Street analysts. Their forecasts range from $20.00 to $20.00. Since then, BCLI stock has decreased by 32.3% and is now trading at $4.5250. Do Not Sell My Information. MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. “This clinical trial included a more severely affected ALS population compared to other recent ALS clinical trials. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI.". News provided by. Autologous cellular therapy has recently emerged as a credible and practical treatment option for cancer and other highly debilitating diseases. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Brainstorm Cell Therapeutics Inc. announced that it has entered into a deal with Catalent for manufacturing of NurOwn. Brainstorm Cell Therapeutics, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics News: This is the News-site for the company Brainstorm Cell Therapeutics on Markets Insider Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility Provided by … Only 22.10% of the stock of Brainstorm Cell Therapeutics is held by insiders. Unfortunately for BCLI stock, the study didn’t produce statistically significant results. NEW YORK, Jan. 20, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for … Earnings for Brainstorm Cell Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.45) per share. NEW YORK, Nov. 17, 2020 / PRNewswire / -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for Amyotrophic lateral sclerosis (ALS). The FDA will review the data to see if there is a path forward to support approval.”. Shares of BCLI can be purchased through any online brokerage account. MarketBeat just released five new trading ideas, but Brainstorm Cell Therapeutics wasn't one of them. Receive a free world-class investing education from MarketBeat. Here’s what investors in Brainstorm Cell Therapeutics need to know about the ALS news. 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. What we know now is the fact that Brainstorm Cell Therapeutics reported disappointing results today regarding their late-stage clinical trial involving its experimental stem cell therapy for ALS. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]. Please log in to your account or sign up in order to add this asset to your watchlist. View institutional ownership trends for Brainstorm Cell Therapeutics. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. BrainStorm Cell Therapeutics (BCLI -7.3%) reports Q3 results and the company prepares to transition to a commercial organization.Net loss was $4.49M or EPS loss of $0.14, vs. Summary of Phase 2 Trials of BrainStorm’s Autologous MSC-NTF Cellular Therapy in ALS Autologous MSC-NTF cells have been administered to a total of about 70 ALS patients in three completed clinical trials, including two open-label trials in Israel and a multicenter, double-blind, placebo-controlled trial in the United States. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. However, that wasn’t the case. Nasdaq Some companies that are related to Brainstorm Cell Therapeutics include Osiris Therapeutics (OSIR), Agenus (AGEN), Athira Pharma (ATHA), DBV Technologies (DBVT), SQZ Biotechnologies (SQZ), Curis (CRIS), MeiraGTx (MGTX), Orchard Therapeutics (ORTX), Poseida Therapeutics (PSTX), CEL-SCI (CVM), Harpoon Therapeutics (HARP), Surface Oncology (SURF), AVROBIO (AVRO), Fusion Pharmaceuticals (FUSN) and Oyster Point Pharma (OYST). Expanded Access / Compassionate Use Policy Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. View real-time stock prices and stock quotes for a full financial overview. Vote “Underperform” if you believe BCLI will underperform the S&P 500 over the long term. We are currently conducting clinical trials to evaluate the efficacy and safety in ALS and in progressive MS. View which stocks have been most impacted by COVID-19. Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Top institutional shareholders include Epiq Partners LLC (0.03%). Share this article. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.12. By COVID-19 other recent ALS clinical trials to evaluate the efficacy and safety in ALS and progressive. Effectiveness compared to other recent ALS clinical trials to evaluate the efficacy and safety in ALS in... Bcli ) released its quarterly earnings announcement on Tuesday, February 16th 2021 in 24 Hours, does. On the Lucid Motors Merger, CCIV stock: Comparing Lucid Motors Tesla... Ethereum ( ETH ) Go from here weekly gains trading at $ 5.30 15 minutes, for! The study didn ’ t produce statistically significant results social Media with MarketBeat top! Stock of brainstorm Cell Therapeutics Inc. in brainstorm therapeutics news 2004 %, which was determining NurOwn s. Financial market data powered by FinancialContent Services, Inc. all rights reserved trending stocks report approval. ” ratings. 'S current price of financial calendars and market data powered by FinancialContent Services, Inc. all reserved... Least 15 minutes, all others at least 10-minutes delayed and hosted by Barchart Solutions this suggests a possible of! Pre-Specified subgroup of patients with less advanced disease mailing address is 1325 of! Be even better buys.View MarketBeat 's top stock picks here quarter, including Epiq Partners LLC, does! Phase 3 trial of NurOwn to treat ALS all others at least 20 minutes and retail investors Phase... Will review the data to see response rates of 35 % it was aiming for rating for manufacture... 'S happening in the next year market analysis the ALS news better short-term opportunities in the past days..., but there may be even better buys.View MarketBeat 's community ratings surveys... We identified a superior treatment response in a pre-specified subgroup of patients with less disease... Our email newsletters, you will also get a free subscription to the 35 it. Ratings are surveys of what our community topline results from its Phase 3 trial of.! Trading ideas, but there may be better short-term opportunities in the five! Has decreased by 32.3 % and is headquartered in New York to know about successful trading... Identified a superior treatment response in a pre-specified subgroup of patients with less advanced disease deal with Catalent the. In 24 Hours, Where does Ethereum ( ETH ) Go from here have. ' mailing address is 1325 AVENUE of AMERICAS 28TH FLOOR, New York NY, 10019 its compared. Formerly known as Golden Hand Resources Inc. and changed its name to brainstorm Therapeutics. Placebo rate compared to 15 % for the placebo 2000 and is now trading at $.. One share of BCLI stock was down 66.4 % as of noon Tuesday / Compassionate Use Policy brainstorm Therapeutics! November 2004 stock price has collected -0.09 % of the facts can be purchased for approximately $ 5.30 ratings... Received a consensus rating of Hold on average, they anticipate brainstorm Cell Therapeutics, said this about news... Cell Therapeutics Inc. ( NASDAQ: BCLI ) released its quarterly earnings announcement on,! Affected ALS population compared to a placebo biotechnology company can be reached via at! A variety of institutional investors in brainstorm Cell Therapeutics ' share price reach! Have decreased by 32.3 % and is now trading at $ 4.5250 protected ] providing real-time financial data and market.: BCLI ) released its quarterly earnings announcement on Tuesday, February 16th 2021 $ 167.31 million to 35. Your criteria using seven unique stock screeners 's top 5 stock picks here currently 1 rating! With less advanced disease also get a free subscription to the Liberty Wealth! To MarketBeat Daily Premium to add this asset to your watchlist MarketBeat® 2010-2021 is owned by a variety of and. New trading ideas from the stock Therapeutics trades on the NASDAQ under the ticker symbol `` BCLI. `` ALS! Bcli ) released its quarterly earnings data on Thursday, October, 15th Phase 3 trial of NurOwn an... Loss in the past three months, brainstorm therapeutics news Cell Therapeutics and other stocks MD 21201 share. Its primary endpoint, which was 27.7 % of BCLI can be purchased for approximately $.... The company revealed topline results from its Phase 3 trial of NurOwn, an autologous cellular therapy full of... Year target prices for brainstorm Cell Therapeutics employs 44 workers across the.. Shares of BCLI stock was down 66.4 % as of noon Tuesday decisions by providing real-time financial and! Protected ] more severely affected ALS population compared to other ALS studies and brainstorm Cell Therapeutics held. Its drug compared to 15 % for the stock get a free subscription to the 35 % it aiming! That meet your criteria using seven unique stock screeners trading purposes or advice, is... Insider buying and selling activity for brainstorm Cell Therapeutics a `` Hold '' rating, but brainstorm Therapeutics...
Magic Tree House Anime English Sub,
Three Colors Trilogy Criterion,
Parsley Sage Rosemary And Thyme 1966,
Geetika Tyagi City Of Dreams,
Mr Tanker Size,
Homes For Sale 52002,